AI呼吸机与海外业务双轮驱动：可孚医疗上半年营收增长近四成

Cofoe Medical, a Changsha-based home healthcare device maker listed on both Shenzhen and Hong Kong stock exchanges, posted first-half revenue of 2.07 billion yuan ($290 million), up 38.5% year-on-year. Net profit rose 20.8% to 202 million yuan. The growth was driven by two engines: AI-powered products and overseas expansion. 

长沙家用医疗器械企业可孚医疗（深港两地上市）发布半年报：上半年营收20.72亿元，同比增长38.51%；净利润2.02亿元，增长20.84%。增长由两大引擎驱动：AI赋能的产品创新与海外市场拓展。

Respiratory support revenue surged 167% to 267 million yuan, fueled by its new AI-powered ventilator C11; TCM therapy devices grew 115%. Overseas revenue hit 210 million yuan, up 117%, supported by EU certification for two blood glucose monitoring systems. The company also established an AI research institute in February and plans a mid-year dividend of 136 million yuan.

呼吸支持业务收入2.67亿元，同比增长167%，新一代AI呼吸机C11贡献显著；中医理疗业务增长115%。海外业务收入2.1亿元，同比增长117%，两款血糖监测系统获欧盟IVDR认证。公司今年2月成立人工智能研究院，并拟实施中期分红1.36亿元。